Abstract. Glioblastoma (GBM) is the most common and aggressive primary brain tumor. The identification of novel molecular prognostic markers of GBM has recently been an area of great interest in neuro-oncology. The methylation status of the MGMT gene promoter is currently a promising molecular prognostic marker, but some controversial data have precluded its clinical use. We analyzed MGMT methylation by methylation-specific PCR in 90 GBM patients from four Portuguese hospitals, uniformly treated with radiotherapy combined with concomitant and adjuvant temozolomide (Stupp protocol). The Kaplan-Meier method was used to construct survival curves, and the log-rank test and a Coxregression model were used to analyze patient survival. The methylation status of MGMT was successfully determined in 89% (80/90) of the tumors. The frequency of tumoral MGMT promoter methylation was 47.5%. The median overall survivals (OSs) were 16 months (95% CI 12.2-19.8) and 13 months (95% CI 13.3-18.7) for patients whose tumors had a methylated or unmethylated MGMT, respectively. Univariate and multivariate analyses did not show any statistically significant association between MGMT methylation status and patient OS (P=0.583 by the log-rank test; P=0.617 by the Cox-regression test) or progression-free survival (P=0.775 by the log-rank test; P=0.691 by the Cox-regression test). None of the patient clinical features were significantly correlated with survival. This is the first study to report the frequency of MGMT methylation among Portuguese GBM patients. Our data did not show statistically significant associations between MGMT promoter methylation and the outcome of GBM patients treated with temozolomide. Additional robust prospective studies are warranted to clarify whether the MGMT status should be used in clinical decisions.
Introduction
Tumors of the central nervous system account for a small percentage of all types of human tumors (1), but encompass a wide variety of distinct disease entities (2) . Data from the GLOBOCAN 2002 database report an incidence of brain and central nervous system tumors in Portugal of ~422 cases per year in males and ~362 cases per year in females (3) . Gliomas are the most common primary brain tumors (2, 4) and encompass a wide variety of tumors thought to originate either from stem cells, glial precursor cells or glial differentiated cells. Astrocytomas are the major histological subtype, accounting for ~75% of all gliomas (4), of which GBM (WHO grade IV) is by far the most common and malignant. The highly infiltrative nature coupled with the high proliferative potential causes this tumor to be particularly devastating, for which no curative therapies are currently available (5, 6) . Two main subtypes of GBM can be distinguished based on their clinical presentation: the most common subtype, primary (or de novo) GBM, develops without the presence of any precursor neoplastic lesion and manifests after a short clinical history (usually less than 3 months); secondary GBMs are much rarer and develop from lower grade tumors (2, 7) .
Despite recent improvements in therapeutic approaches, treatment still remains mostly palliative, and GBM patients usually present an extremely poor prognosis. The median survival is typically reported to be ~12 months in clinical trials (2) , but a large population-based study in 2004 reported a median survival for these patients of ~5 months, with onlỹ 18% and ~3% of the patients surviving over 1 and 2 years, respectively (8) . The current paradigm of therapy for patients with newly diagnosed GBM includes surgical resection (when feasible), radiotherapy and chemotherapy. A phase III trial by Stupp et al clearly showed that GBM patients treated with radiotherapy combined with concomitant and adjuvant temozolomide (TMZ, an orally administered alkylating agent), also known as TMZ-based chemoradiation, had an increased overall survival (OS) compared with patients treated with radiotherapy alone (9) , establishing a new standard in the management of these tumors. Despite a significant improvement, it is important to note that this treatment resulted in a small difference in overall survival. In order to improve the clinical outcome of these patients, it is widely acknowledged that the ideal treatment of GBMs must be individualized, based on the particular features of the tumor. Indeed, the prognosis of these patients is quite variable and unpredictable. Some of the most well-established prognostic markers in GBM include patient clinical features, such as age, Karnofsky performance status (KPS) (10) and extent of tumor resection; however, these markers do not satisfactorily predict patient outcome (11) . One of the major goals of current neurooncology research is to identify robust and clinically relevant molecular markers that can add value to those more classic clinical prognostic factors.
MGMT (O-6-methylguanine-DNA methyltransferase), a gene located on chromosome 10q26, encodes a DNA-repair enzyme that has been shown to contribute to the chemoresistance of GBM cells to alkylating agents (12) . Specifically, a landmark study by Hegi et al showed that GBM patients whose tumors had a methylated MGMT promoter presented a significantly longer median OS (21.7 months) and 2-year survival rate (46%) when treated with TMZ-based chemoradiation compared with patients without MGMT promoter methylation who were treated similarly (median survival of 12.7 months and 2-year survival rate of 13.8%) (13) . Additionally, in the data set of Hegi et al, MGMT promoter methylation was an independent favorable prognostic factor, irrespective of treatment. Due to its potential prognostic value, the assessment of MGMT methylation status is currently a common practice in clinical trials involving GBM patients (14) . Despite these striking findings, there is a significant body of controversial data surrounding the reproducibility of these results, questioning the true implication of MGMT as a GBM prognostic marker and/or a specific predictor of TMZbased chemotherapy (15) (16) (17) . In this context, we aimed to assess the frequency and clarify the prognostic capacity of MGMT promoter methylation in a set of Portuguese GBM patients uniformly treated with TMZ-based chemoradiation.
Materials and methods
Human tumor samples. Human tumor samples were obtained from primary GBM patients newly diagnosed according to the WHO criteria (2) and surgically resected between 2004 and 2007 at 4 hospitals in northern Portugal: Hospital São João (n=36), Hospital Pedro Hispano (n=33), Hospital Santo António (n=11) and Hospital São Marcos (n=10). All patients underwent radiotherapy plus continuous concomitant TMZ after surgery, followed by maintenance cycles of TMZ, according to the Stupp protocol (9). Extension of tumor resection was assessed by the neurosurgeon and by postoperative magnetic resonance imaging (MRI) and were classified as gross resection (total or subtotal) or biopsy. The clinicopathological features are summarized in Table I . All procedures followed in this study were in accordance with institutional ethical standards, and the biological samples were unlinked and unidentified from their donors. Follow-up data were available for all patients as of July 2008, and were collected through direct interview with patients or their relatives and by review of in-hospital patient files.
DNA isolation. DNA was isolated by macrodissection from 10-μm sections of formalin-fixed paraffin-embedded tumor tissue samples, avoiding the harvesting of surrounding normal brain tissue by comparing each slide with the corresponding hematoxylin and eosin (H&E)-stained slide (marked for the area of tumoral tissue) (18) . The recovered tissues were processed with the QIAamp ® DNA Micro Kit (Qiagen) following the manufacturer's instructions. DNA quality control and yield were assessed by spectrophotometry using Nanodrop™.
DNA bisulfite treatment and MGMT methylation-specific PCR analysis. Genomic DNA was subjected to bisulfite treatment using the EZ DNA Methylation-Gold™ Kit (Zymo Table I . Clinicopathological features of glioblastoma patients treated with temozolomide-based chemoradiation (n=90).
Age, years (median ± SD) 56±11
Karnofsky performance score ≥80 (n) 48 <80 (n) 42
Extent of resection Total or subtotal (n) 81
following the manufacturer's instructions. The promoter MGMT methylation-specific polymerase chain reactions (MSP) were performed using a two-step nested approach, and the results were confirmed by one-step MSP in a subset of tumors as previously described (13, 19) . Peripheral blood DNA from tumor-free controls and CpGenome™ Universal Methylated DNA (Chemicon International) were used as MGMT unmethylated and methylated controls, respectively. The PCR products were resolved on 4% lowmelting point agarose gels. Analysis of MSP data was performed by investigators who were blind to the clinical data.
Statistical analyses. The Kaplan-Meier method was used to estimate OS and progression-free survival (PFS), and the logrank test was used to assess the differences. OS was measured from the time of surgical resection to patient death, or the last date when the patient was known to be alive. PFS time was defined as the time from surgical resection to the time of demonstrated tumor growth on follow-up imaging, or evidence of neurological decline. Multivariate survival analyses by use of Cox proportional hazards models (backward selection) were performed to adjust for the effects of potential confounding factors, including patient age (used as a continuous variable), gender, KPS and extent of tumor resection. All statistical tests were two-sided, and significance was considered at values of P<0.05. Data analysis was performed using SPSS 16.0 software (SPSS, Inc.).
Results
Patient clinical features which may have an effect on prognosis, such as gender, age at diagnosis, KPS and extent of tumor resection, are summarized in Table I . The tumoral MGMT methylation status was successfully determined by MSP in 80 tumor samples (89%), of which 38 GBMs (47.5%) had a methylated MGMT promoter. Fig. 1 presents a typical MSP analysis of the methylation status of the MGMT promoter.
Considering the whole tumor set, independently of clinical features or MGMT methylation status, the median OS and PFS were 14 months (95% CI 11.5-16.5) and 9 months (95% CI 7.5-10.5), respectively. The overall 2-year survival rate was 16.7%. Table II summarizes the median OS and median PFS of patients based on clinicopathological features (gender, age, KPS and extent of tumor resection) and MGMT methylation status. By using the log-rank test, no statistically significant associations were detected between each individual variable and GBM patient OS or PFS (P>0.05) (Table II) . Similarly, a multivariate Cox proportional model did not show any statistically significant correlation between the studied variables and GBM patient outcome (P>0.05) (Table II) . Nevertheless, patients whose tumors had a methylated MGMT promoter showed a slightly improved median OS of 16 months (95% CI 12.2-19.8) as compared to patients with an unmethylated MGMT promoter (13 months, 95% CI 11.1-14.9; Fig. 2 ), but the differences were not statistically significant (P=0.583 by the univariate test; P=0.617 by the multivariate ONCOLOGY REPORTS 23: 1655 -1662 , 2010 Table II. Associations between clinical features or status of tumoral MGMT promoter methylation and prognosis of GBM patients, assessed by univariate (log-rank test) and multivariate (Cox-regression) analyses. 
a Median survival and 95% confidence intervals, in months.
b Patient age was used as a continuous variable for the Cox-regression model. KPS, Karnofsky performance status. Table II ). The median PFS was closely similar between patients whose tumors had methylated (9 months, 95% CI 5.0-13.0) and unmethylated (10 months, 95% CI 8.1-12.0) MGMT promoter (P=0.775 by the log-rank test; P=0.691 by the Cox model; Table II ). The 2-year survival rate was 15.8% and 16.7% in patients with methylated and unmethylated MGMT, respectively (P=0.915).
Discussion
GBM is a particularly devastating disease as no curative therapies are available, and very few well-established prognostic factors have been identified. Many recent efforts in the field of neuro-oncology are directed to developing more efficient therapies, but only a small fraction of patients experience significant clinical benefit and prolonged survival. Despite the variability of the clinical responses, the majority of patients with GBM are presently treated in a uniform standardized way, following a 'one fits all' therapeutic approach, regardless of the individual molecular characteristics of each tumor that most likely affect patient prognosis. Consequently, many patients display minor responses and major therapy-related toxicities.
The recent introduction of radiotherapy plus concomitant and adjuvant TMZ treatment for GBM has led to a small but significant improvement in patient outcome (9) ; however, the responses are still very poor and unpredictable. While the EORTC-NCIC trial by Hegi et al (13) implicated the status of MGMT promoter methylation as a biomarker of GBM patient response to TMZ, all GBM patients continue to be treated with TMZ, regardless of their MGMT status (13) . To note, the conclusions of Hegi et al were somewhat confounded and questioned due to several limitations of the study. First, the studies were performed retrospectively on a subset of patients from whom adequate tumor tissue was available. Second, although the difference in survival based on MGMT methylation status was highly significant, more than half of the methylated MGMT patients (with a predictably favorable outcome) did not survive for 2 years, while ~15% of the patients with unfavorable unmethylated MGMT did survive over 2 years. Third, MGMT methylation was associated with improved outcomes both in the temozolomide-based chemoradiation and radiation-only arms, suggesting that it may partly be a prognostic marker associated with the nature of the tumor, rather than a truly therapy-specific predictive marker. Lastly, many of the patients in the radiation-only arm also received TMZ at recurrence. Regardless, this was a landmark study suggesting that methylation of MGMT is both a prognostic marker and a specific marker of response to TMZ in GBM patients. Indeed, the conclusions of Hegi et al were recently corroborated by a 5-year analysis of the EORTC-NCIC trial, where Stupp et al (20) confirmed that the methylation of the MGMT promoter is associated with better outcome and benefit from TMZ chemotherapy. The first study implicating a correlation between MGMT levels and survival of malignant glioma patients dates back to 1998, when Jaeckle et al showed that patients treated with BCNU (a nitrosourea used as a chemotherapeutic agent) whose tumors had low or undetectable levels of MGMT had an improved survival as compared to those whose tumors had detectable MGMT activity (21) . Soon after, Esteller et al reported for the first time that methylation of the MGMT gene promoter led to loss of MGMT expression in human tumors in vivo (22) . In 2000, Esteller et al found that a methylated MGMT promoter in malignant glioma was associated with improved overall and PFS, independently of patient age and KPS (12) . Mechanistically, the ability of functional MGMT protein to remove the cytotoxic chemotherapy-induced alkyl groups from the O 6 -guanine of DNA, and thus prevent killing of tumor cells, supported the clinical Table III . Prognostic significance of MGMT methylation in glioblastoma reported in the literature.
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Author (Reference) Year n Treatment Effect of MGMT methylation on survival a c MGMT promoter was considered methylated by pyrosequencing when ≥9% of CpG dinucleotides were methylated. d The set of 30 GBM patients in this study compared long-term and short-term survivors only.
-------------------PFS OS -----------------------------------------------------------------------------------------------------
e Statistically significant by univariate analysis, but not significant by multivariate analysis.
f MGMT methylation status was determined by a microarray-based DNA methylation analysis. g Patients with a methylated MGMT promoter had a significantly worse prognosis than unmethylated cases.
- ---------------------------------------------------------------------------------------------------- finding that lack of MGMT expression was associated with improved outcomes. Whether this molecular marker should ultimately direct the treatment of newly diagnosed patients is still a fundamental and controversial question. Much of the controversy surrounding the prognostic value of MGMT is partly due to studies including very heterogeneous groups of patients with different glioma subtypes and who underwent different treatment regimens. In addition, not all studies analyzed the MGMT status at the level of DNA methylation in the promoter region by methylation-specific polymerase chain reaction (MSP); some studies focused on mRNA expression by RT-PCR and protein levels by immunohistochemistry and quantitative immunofluorescence (15) . Nevertheless, contradictory results are also reported even in studies that evaluated the influence of MGMT promoter methylation on the prognosis of patients with GBM (Table III) (12, 13, 16, 17, 20, .
In our study, we attempted to clarify whether MGMT methylation is a biomarker of clinical outcome in GBM patients treated with the recently introduced TMZ-based chemoradiation protocol and how it compares to the prognostic value of classic clinicopathological factors. By studying a set of 90 GBM patients from northern Portugal, we were unable to detect any significant correlations between patient clinical features, MGMT methylation status and prognosis. Other studies have also failed to show such correlations (Table III) . To note, the frequency of MGMT promoter methylation in our data set is similar to the previously reported frequencies (13, 23, 30, 33, 35, 55) . Additionally, the median OS and median PFS in our set of GBM patients are in line with other recently published studies (20, 23, 55) . Some possible limitations of our study include the relatively small sample size, which may be a limiting factor in achieving statistical significance, and the fact that we analyzed a multicenter tumor set collected from 4 independent institutions. Nevertheless, our sample size compares favorably with other similar studies published in the literature (Table III) ; additionally, our population-based study is likely to closely illustrate the difficulties in identifying significant determinants of patient survival, as this type of study is typically less controlled and more heterogeneous than well-designed prospective clinical trials. Obviously, the argument that MGMT methylation does not predict GBM patient response to this therapeutic regimen is still equally valid. It is also relevant to stress that the most appropriate method to assess MGMT status in gliomas is quite controversial. Validated and commercially available MGMT methylation assays have not yet been approved for clinical use and may indeed be technically challenging. In spite of a recent report arguing in favor of the feasibility and reliability of nested, gel-based methylation-specific PCR (MSP) analysis, suggesting it could be routinely implemented in the clinical setting (56) , the use of MSP is often considered not to be so straightforward (57) (58) (59) (60) . Its use has raised some concerns due to inter-and intra-test variability and sensitivity and specificity issues (57, 59) . One recent report argues that a quantitative MSP test for MGMT methylation is more specific than conventional gel-based MSP (61) . Furthermore, MGMT silencing can occur through methylation of specific cytosines within the CpG island (62); thus, it is important to determine which CpG dinucleotides are the most predictive of potential MGMT silencing. A recent study using pyrosequencing methylation analysis argues that a new set of CpG dinucleotides in the MGMT promoter CpG island is more robust in predicting gene silencing than those classically tested by the MSP assay (63) . Conceptually, while a methylated MGMT promoter precludes gene expression, the absence of such methylation does not necessarily translate into activation of gene expression, as specific transcription factors [e.g., Sp1 (64) and TP53 (65) ], permissive chromatin states (64, (66) (67) (68) (69) , and absence of negative transcriptional regulators (e.g., IFN-ß) are also required. Additionally, it is reasonable to assume that, given the heterogeneity of MGMT expression within individual tumors, a fraction of the cells within the entire tumor load may lack MGMT expression, despite an unmethylated MGMT status, and may therefore be sensitive to temozolomide. A recent study also suggests that variation in MGMT promoter methylation can occur within the same tumor after treatment (70) , stressing that clinical decisions based on MGMT require caution. Despite these considerations as well as the consensual belief that additional molecular markers of GBM patient outcome are important in determining the tumor response to therapy, if the relevance of MGMT promoter methylation status in GBM is corroborated by an ongoing phase III large study by the Radiation Therapy Oncology Group (RTOG 0525), patients with unmethylated MGMT promoter may be selected for alternative treatment options in the future. Potential alternative strategies to overcome MGMT-mediated chemoresistance include: (i) use of temozolomide together with MGMT-inactivating drugs (71,72) such as O 6 -benzylguanine (73, 74) or inhibitors of other DNA repair enzymes; and (ii) use of dose-intensive temozolomide regimens (71) which deplete MGMT levels more rapidly than lower doses (75) .
In conclusion, our study is the first to report the frequency of tumoral MGMT promoter methylation among Portuguese GBM patients and to analyze the correlations between clinical features, MGMT status and outcome in a set of patients uniformly treated with concomitant and adjuvant TMZ chemoradiation. In light of our data, together with the controversies reported in the literature, further studies are warranted to clarify the clinical prognostic relevance of MGMT methylation in GBM.
